ESC Premium Access

Cardioprotective effects of a novel designer C-type natriuretic peptide-based therapeutic, C53 , for the prevention of post-myocardial infarction heart failure

Presentation

About the speaker

Mr Yang Chen

Mayo Clinic, Rochester (United States of America)
0 follower

6 more presentations in this session

Feasibility and efficacy of early donepezil with or without metoprolol in reperfused myocardial infarction rats

Speaker: Doctor M. Li (Osaka, JP)

Thumbnail

The best of two worlds: Vascular protection and decongestion without RAAS stimulation mediated by a novel dual acting V1a/V2 vasopressin receptor antagonist

Speaker: Doctor P. Kolkhof (Wuppertal, DE)

Thumbnail

Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat

Speaker: Doctor H. Yip (Kaohsiung, TW)

Thumbnail

Empagliflozin improves left ventricular diastolic function in db/db mice without altering cardiac expression of enzymes relevant for ketone body or branched chain amino acid catabolism.

Speaker: Miss J. Moellmann (Aachen, DE)

Thumbnail

Empagliflozin prevention of heart failure development in diabetes is associated with an improvement in cardiac energy producition

Speaker: Professor S. Verma (Toronto, CA)

Thumbnail

Access the full session

Targeting reverse remodelling in heart failure

Speakers: Mr Y. Chen, Doctor M. Li, Doctor P. Kolkhof, Doctor H. Yip, Miss J. Moellmann...
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk